

Date: 12th February, 2025

To,
Department of Corporate Services,
BSE Limited
P. J. Towers,
Dalal Street,
Mumbai-400 001

Dear Sir/Madam,

Sub.: Integrated Filing (Financials) for the quarter and nine months ended December 31, 2024

Ref Security ID: ADLINE/ Scrip Code: 524604

Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31 2024, read with BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated January 2, 2025, we are submitting herewith the Integrated Filing (Financials) for the Quarter ended December 31, 2024.

A.	Financial Results	Attached as Annexure-1
B.	Statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc.	Not Applicable
C.	Format for disclosing outstanding default on loans and debt securities	Not applicable as there is no default on loans and debt securities outstanding as on 31st December 2024
D.	Format for disclosure of related party transactions (applicable only for half yearly filings i.e., 2nd and 4th quarter)	Not Applicable for this Quarter
E.	Statement on impact of audit qualifications (for audit report with modified opinion) submitted along-with annual audited financial results (standalone and consolidated separately) (applicable only for annual filing i.e., 4th quarter)	Not Applicable for this quarter

You are requested to kindly take the same on record and acknowledge.

Thanking You,

For, Adline Chem Lab Limited

Ritu Singh
Company Secretary & Compliance Officer
Membership No.: A24934

Encl: as above


CIN : L24231GJ1988PLC010956

ADLINE CHEM LAB LIMITED (Formerly Kamron Laboratories Limited)

Registered Office : 403, Sarthik II, Opp. Rajpath Club, S. G. Highway, Bodakdev, Ahmedabad - 380 054, Gujarat, INDIA.
Phone: 079 2687 0954 | E-mail : secretarial.adlinechemlab@gmail.com | Website: www.kamronlabs.com


The Board of Directors**ADLINE CHEMLAB LIMITED****Independent Limited Review Report on the quarterly unaudited Standalone Financial Results of the Company pursuant to the regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**

1. We have reviewed the accompanying statement of unaudited financial results of Adline Chem Lab Ltd. (the "Company") for the quarter ended December 31, 2024 which include financial results ended on that date together with the relevant notes thereon (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (The "Listing Regulations, 2015"). The Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. This Statement, which is the responsibility of the Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.



4. Based on our review conducted as above, nothing except for the point no. 5 stated below has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with applicable Indian Accounting Standard ('Ind AS') and other recognised accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. We draw attention to the related party transaction entered into by the Company with Vivanza Lifescience Private Limited, an unlisted entity within the group. The transaction was conducted in the ordinary course of business for which the entities have entered into an agreement and complies with the provisions of Section 188 of the Companies Act, 2013. The Company has not obtained prior shareholders' approval for this transaction as set forth in Regulation 23(4) of the Listing Regulation Act, 2015. Our opinion is not modified in respect of this matter.

For Jain Kedia & Sharma
Chartered Accountants
FRN: 103920W



Tarak Shah

Tarak Shah
Partner

Place: Ahmedabad

Date: February 04, 2025

Membership No. 182100

UDIN:25182100BMOCZQ7152

ADLINE CHEMLAB LIMITED
 Regd. Office: 403, Sarthik 2, Opp. Rajpath Club, S. G. Highway, Ahmedabad 380054
 CIN : L24231GJ1988PLC010956
 Phone: 079-2687052/53 email: secretarialadlinechemlab@gmail.com website:www.adlinechem.com
STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED 31st December, 2024

Particulars	Quarter Ended			Nine Month Ended		Year Ended
	31st Dec 2024	30th Sep 2024	31st Dec 2023	31st Dec 2024	31st Dec 2023	31st Mar 2024
	Unaudited	Unaudited	Restated	Unaudited	Restated	Restated
Revenue from operations	-	-	-	-	-	-
Other income	-	-	-	-	-	-
Total income	-	-	-	-	0.01	0.01
					0.01	0.01
Expenses						
Cost of materials consumed	-	-	-	-	-	-
Purchase of Stock in Trade	-	-	-	-	-	-
Changes in inventories of finished goods, Stock-in-Trade and work-in-progress	-	-	-	-	-	-
Employee benefits expense	4.72	4.71	0.50	13.04	3.09	4.36
Finance costs	3.48	3.39	3.15	10.18	9.22	12.44
Depreciation and amortization expense	-	-	-	-	-	-
Other expenses	4.95	2.02	-0.43	13.52	8.37	13.49
Total expenses	13.14	10.13	3.22	36.74	20.67	30.29
Profit/(loss) before exceptional items and tax	(13.14)	(10.13)	(3.22)	(36.74)	(20.66)	(30.28)
Exceptional Items	-	-	-	-	-	-
Profit/(loss) before tax	(13.14)	(10.13)	(3.22)	(36.74)	(20.66)	(30.28)
Tax expense:	0.88	(0.86)	(0.72)	(2.58)	(2.25)	(3.10)
Current tax	-	-	-	-	(2.32)	-
Deferred tax	0.88	(0.86)	(0.79)	(2.58)	0.07	(3.16)
Prior period tax	-	-	0.07	-	-	0.07
Profit (Loss) for the period from continuing operations	(12.26)	(9.27)	(2.49)	(34.16)	(18.41)	(27.18)
Profit/(loss) from discontinued operations	-	-	-	-	-	-
Tax expense of discontinued operations	-	-	-	-	-	-
Profit/(loss) from Discontinued operations (after tax)	-	-	-	-	-	-
Profit/(loss) for the period	(12.26)	(9.27)	(2.49)	(34.16)	(18.41)	(27.18)
Other Comprehensive Income	0.46	0.46	-	1.37	-	0.05
Items that will not be reclassified to profit or loss (Net off tax)	0.46	0.46	-	1.37	-	0.05
Benefit due to actuarial valuation of gratuity	0.61	0.61	-	1.84	-	0.06
Deferred tax	(0.15)	(0.15)	-	(0.46)	-	(0.02)
Items that will be reclassified to profit or loss (Net of tax)	-	-	-	-	-	-
Total Comprehensive Income for the period	(11.81)	(8.81)	(2.49)	(32.79)	(18.41)	(27.13)
Paid-up equity share capital (Face Value of the Share Rs. 10/- each)	585.00	585.00	585.00	585.00	585.00	585.00
Earnings per equity share [Not Annualised]:						
Basic	(0.02)	(0.02)	(0.00)	(0.06)	(0.03)	(0.05)
Diluted	(0.02)	(0.02)	(0.00)	(0.06)	(0.03)	(0.05)

Notes:

- This statement has been prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 Accounting Standards Rules, 2015 (as amended). The statutory auditors of the company have carried out limited review of the financial results for the quarter ended December 31, 2024.
- These results have been reviewed and recommended for adoption by the Audit Committee in its meeting held on February 04, 2025, and approved by the Board of Directors at its meeting held on February 04, 2025. The Statutory Auditors Report does not have any qualification | modification.

For, ADLINE CHEMLAB LIMITED

SARANG BHARATBHAI PATHAK
 MANAGING DIRECTOR
 DIN:02663344

Place: Ahmedabad
 Date: February 04, 2025

